STOCK TITAN

[Form 4] ProMIS Neurosciences Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On 03/13/2025 Michael S. Gordon reported changes in his beneficial ownership of ProMIS Neurosciences Inc. (PMN). The Form 4 shows a disposition of 48,333 common shares under Code J, and identifies indirect holdings of 2,435,029 shares through "Promis" and previously through "Title 19 Acies." The filing explains that Title 19 Aciess ownership was assigned to Skye Peak Partners LLC effective 01/01/2025 and management of that entity changed, removing Gordons investment control over those shares.

The Form notes that, based on the issuer's later filing showing 51,806,497 shares outstanding, Gordons ownership fell below 10% as of this Form 4 filing date; it also states Gordon held more than 10% when the Form 4 was originally due. The Form is signed 08/14/2025 and contains an explanatory remark about timing and ownership calculations.

Il 13/03/2025 Michael S. Gordon ha comunicato modifiche nella sua partecipazione in ProMIS Neurosciences Inc. (PMN). Il Modulo 4 riporta la cessione di 48.333 azioni ordinarie ai sensi del Codice J e indica una detenzione indiretta di 2.435.029 azioni tramite "Promis" e, in precedenza, tramite "Title 19 Acies". La segnalazione spiega che la proprietà di Title 19 Acies è stata trasferita a Skye Peak Partners LLC con efficacia 01/01/2025 e che la gestione di tale entità è cambiata, privando Gordon del controllo degli investimenti su quelle azioni.

Il Modulo rileva inoltre che, sulla base di una successiva comunicazione dell'emittente che indica 51.806.497 azioni in circolazione, la partecipazione di Gordon è scesa sotto il 10% alla data di presentazione del presente Modulo 4; si precisa anche che Gordon deteneva oltre il 10% quando il Modulo 4 era originariamente dovuto. Il Modulo è firmato il 14/08/2025 e contiene una nota esplicativa sui calcoli e sui tempi relativi alla proprietà.

El 13/03/2025 Michael S. Gordon informó cambios en su participación beneficiaria de ProMIS Neurosciences Inc. (PMN). El Formulario 4 muestra una disposición de 48.333 acciones ordinarias bajo el Código J e identifica tenencias indirectas de 2.435.029 acciones a través de "Promis" y anteriormente mediante "Title 19 Acies". La presentación explica que la titularidad de Title 19 Acies fue asignada a Skye Peak Partners LLC con efecto 01/01/2025 y que la gestión de esa entidad cambió, eliminando el control de inversión de Gordon sobre esas acciones.

El Formulario señala además que, basándose en una presentación posterior del emisor que muestra 51.806.497 acciones en circulación, la participación de Gordon cayó por debajo del 10% en la fecha de presentación de este Formulario 4; también indica que Gordon poseía más del 10% cuando el Formulario 4 debía haberse presentado originalmente. El Formulario está firmado el 14/08/2025 y contiene una anotación explicativa sobre el momento y los cálculos de propiedad.

2025년 3월 13일 Michael S. Gordon은 ProMIS Neurosciences Inc.(PMN)에 대한 실소유 변동을 신고했습니다. Form 4는 코드 J에 따른 보통주 48,333주의 처분을 기재하고, "Promis"를 통해 그리고 이전에는 "Title 19 Acies"를 통해 간접 보유한 2,435,029주를 식별합니다. 신고서는 Title 19 Acies의 소유권이 2025년 1월 1일부로 Skye Peak Partners LLC에 양도되었으며 해당 법인의 관리가 변경되어 Gordon의 투자 통제권이 해당 주식에서 제거되었음을 설명합니다.

또한 Form은 발행인이 이후 제출한 서류에서 유통 주식 수가 51,806,497주로 표시된 것을 근거로, 이 Form 4 제출일 기준 Gordon의 보유율이 10% 미만으로 떨어졌음을 기록하고 있으며; 원래 Form 4 제출 기한에는 Gordon이 10%를 초과 보유하고 있었다고 명시합니다. 해당 Form은 2025년 8월 14일에 서명되었고 소유권 계산 및 시점에 관한 설명이 포함되어 있습니다.

Le 13/03/2025, Michael S. Gordon a signalé des modifications de sa détention effective de ProMIS Neurosciences Inc. (PMN). Le formulaire 4 indique une cession de 48 333 actions ordinaires en vertu du code J et identifie une détention indirecte de 2 435 029 actions via "Promis" et auparavant via "Title 19 Acies". Le dépôt précise que la propriété de Title 19 Acies a été transférée à Skye Peak Partners LLC à compter du 01/01/2025 et que la gouvernance de cette entité a changé, ce qui a retiré à Gordon le contrôle des investissements sur ces actions.

Le formulaire note également que, d'après une déclaration ultérieure de l'émetteur faisant état de 51 806 497 actions en circulation, la participation de Gordon est tombée en dessous de 10 % à la date de dépôt de ce formulaire 4 ; il indique aussi que Gordon détenait plus de 10 % lorsque le formulaire 4 était initialement exigible. Le formulaire est signé le 14/08/2025 et contient une remarque explicative sur le calendrier et les calculs relatifs à la détention.

Am 13.03.2025 meldete Michael S. Gordon Änderungen seines wirtschaftlichen Eigentums an ProMIS Neurosciences Inc. (PMN). Das Formular 4 weist eine Veräußerung von 48.333 Stammaktien gemäß Code J aus und benennt eine indirekte Beteiligung von 2.435.029 Aktien über "Promis" und zuvor über "Title 19 Acies". In der Einreichung wird erläutert, dass das Eigentum an Title 19 Acies mit Wirkung zum 01.01.2025 an Skye Peak Partners LLC übertragen wurde und sich die Geschäftsführung dieser Einheit geändert hat, wodurch Gordons Anlagesteuerung über diese Aktien entfiel.

Das Formular stellt ferner fest, dass Gordons Beteiligung auf Basis einer späteren Meldung des Emittenten, die 51.806.497 ausgegebene Aktien ausweist, zum Zeitpunkt der Einreichung dieses Formulars 4 unter 10 % gefallen ist; es wird auch angegeben, dass Gordon über 10 % hielt, als das Formular 4 ursprünglich fällig war. Das Formular ist vom 14.08.2025 unterschrieben und enthält einen erläuternden Hinweis zu Zeitpunkten und Berechnungen der Eigentumsverhältnisse.

Positive
  • Disclosure of reassignment and management changes for Title 19 Acies is transparent and explained in the filing
  • Reported specific amounts: disposition of 48,333 common shares and indirect ownership of 2,435,029 shares via Promis
Negative
  • Late filing: Form is signed 08/14/2025 and remarks indicate timing issues relative to when the Form 4 was due
  • Ownership threshold uncertainty: filing notes ownership dropped below 10% based on a later outstanding-share count, implying potential prior period reporting complexity

Insights

TL;DR: Insider reported a modest sale and a reallocation of indirect holdings that reduced his reported ownership below 10%.

The 48,333-share disposition is small relative to the issuers stated outstanding shares (51.8 million), so the direct market impact of this single reported sale is likely limited. The more material element is the reassignment of Title 19 Acies to Skye Peak Partners LLC effective 01/01/2025 and the accompanying change in management and investment control, which legally removes Gordons pecuniary interest in those shares. The filing also discloses a timing/filing issue: Gordon asserts he exceeded 10% when the Form 4 was due but, using the issuers later outstanding share count, his ownership is below 10% at filing. For investors, this is a disclosure of changing indirect ownership and a late-filed Form 4 rather than a large open-market liquidation.

TL;DR: Governance change: transfer of management and loss of investment control over an entity holding PMN shares; disclosure timing is notable.

The assignment of Title 19 Acies to Skye Peak Partners LLC and replacement of Gordon as sole manager with two other managers alters the governance and control profile of the entity that held PMN shares. That change is explicitly stated to remove Gordons pecuniary interest in those shares. The remarks indicate ownership threshold calculations and a late-filed Form 4 (signed 08/14/2025), which is relevant for compliance review but not presented as a regulatory sanction or litigation. This filing should prompt internal review of reporting timeliness and confirm denominators used for ownership thresholds.

Il 13/03/2025 Michael S. Gordon ha comunicato modifiche nella sua partecipazione in ProMIS Neurosciences Inc. (PMN). Il Modulo 4 riporta la cessione di 48.333 azioni ordinarie ai sensi del Codice J e indica una detenzione indiretta di 2.435.029 azioni tramite "Promis" e, in precedenza, tramite "Title 19 Acies". La segnalazione spiega che la proprietà di Title 19 Acies è stata trasferita a Skye Peak Partners LLC con efficacia 01/01/2025 e che la gestione di tale entità è cambiata, privando Gordon del controllo degli investimenti su quelle azioni.

Il Modulo rileva inoltre che, sulla base di una successiva comunicazione dell'emittente che indica 51.806.497 azioni in circolazione, la partecipazione di Gordon è scesa sotto il 10% alla data di presentazione del presente Modulo 4; si precisa anche che Gordon deteneva oltre il 10% quando il Modulo 4 era originariamente dovuto. Il Modulo è firmato il 14/08/2025 e contiene una nota esplicativa sui calcoli e sui tempi relativi alla proprietà.

El 13/03/2025 Michael S. Gordon informó cambios en su participación beneficiaria de ProMIS Neurosciences Inc. (PMN). El Formulario 4 muestra una disposición de 48.333 acciones ordinarias bajo el Código J e identifica tenencias indirectas de 2.435.029 acciones a través de "Promis" y anteriormente mediante "Title 19 Acies". La presentación explica que la titularidad de Title 19 Acies fue asignada a Skye Peak Partners LLC con efecto 01/01/2025 y que la gestión de esa entidad cambió, eliminando el control de inversión de Gordon sobre esas acciones.

El Formulario señala además que, basándose en una presentación posterior del emisor que muestra 51.806.497 acciones en circulación, la participación de Gordon cayó por debajo del 10% en la fecha de presentación de este Formulario 4; también indica que Gordon poseía más del 10% cuando el Formulario 4 debía haberse presentado originalmente. El Formulario está firmado el 14/08/2025 y contiene una anotación explicativa sobre el momento y los cálculos de propiedad.

2025년 3월 13일 Michael S. Gordon은 ProMIS Neurosciences Inc.(PMN)에 대한 실소유 변동을 신고했습니다. Form 4는 코드 J에 따른 보통주 48,333주의 처분을 기재하고, "Promis"를 통해 그리고 이전에는 "Title 19 Acies"를 통해 간접 보유한 2,435,029주를 식별합니다. 신고서는 Title 19 Acies의 소유권이 2025년 1월 1일부로 Skye Peak Partners LLC에 양도되었으며 해당 법인의 관리가 변경되어 Gordon의 투자 통제권이 해당 주식에서 제거되었음을 설명합니다.

또한 Form은 발행인이 이후 제출한 서류에서 유통 주식 수가 51,806,497주로 표시된 것을 근거로, 이 Form 4 제출일 기준 Gordon의 보유율이 10% 미만으로 떨어졌음을 기록하고 있으며; 원래 Form 4 제출 기한에는 Gordon이 10%를 초과 보유하고 있었다고 명시합니다. 해당 Form은 2025년 8월 14일에 서명되었고 소유권 계산 및 시점에 관한 설명이 포함되어 있습니다.

Le 13/03/2025, Michael S. Gordon a signalé des modifications de sa détention effective de ProMIS Neurosciences Inc. (PMN). Le formulaire 4 indique une cession de 48 333 actions ordinaires en vertu du code J et identifie une détention indirecte de 2 435 029 actions via "Promis" et auparavant via "Title 19 Acies". Le dépôt précise que la propriété de Title 19 Acies a été transférée à Skye Peak Partners LLC à compter du 01/01/2025 et que la gouvernance de cette entité a changé, ce qui a retiré à Gordon le contrôle des investissements sur ces actions.

Le formulaire note également que, d'après une déclaration ultérieure de l'émetteur faisant état de 51 806 497 actions en circulation, la participation de Gordon est tombée en dessous de 10 % à la date de dépôt de ce formulaire 4 ; il indique aussi que Gordon détenait plus de 10 % lorsque le formulaire 4 était initialement exigible. Le formulaire est signé le 14/08/2025 et contient une remarque explicative sur le calendrier et les calculs relatifs à la détention.

Am 13.03.2025 meldete Michael S. Gordon Änderungen seines wirtschaftlichen Eigentums an ProMIS Neurosciences Inc. (PMN). Das Formular 4 weist eine Veräußerung von 48.333 Stammaktien gemäß Code J aus und benennt eine indirekte Beteiligung von 2.435.029 Aktien über "Promis" und zuvor über "Title 19 Acies". In der Einreichung wird erläutert, dass das Eigentum an Title 19 Acies mit Wirkung zum 01.01.2025 an Skye Peak Partners LLC übertragen wurde und sich die Geschäftsführung dieser Einheit geändert hat, wodurch Gordons Anlagesteuerung über diese Aktien entfiel.

Das Formular stellt ferner fest, dass Gordons Beteiligung auf Basis einer späteren Meldung des Emittenten, die 51.806.497 ausgegebene Aktien ausweist, zum Zeitpunkt der Einreichung dieses Formulars 4 unter 10 % gefallen ist; es wird auch angegeben, dass Gordon über 10 % hielt, als das Formular 4 ursprünglich fällig war. Das Formular ist vom 14.08.2025 unterschrieben und enthält einen erläuternden Hinweis zu Zeitpunkten und Berechnungen der Eigentumsverhältnisse.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GORDON MICHAEL S

(Last) (First) (Middle)
C/O TROVE,
40 BROAD STREET, 8TH FLOOR

(Street)
BOSTON MA 02109

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ProMIS Neurosciences Inc. [ PMN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
Officer (give title below) X Other (specify below)
See Remarks section.
3. Date of Earliest Transaction (Month/Day/Year)
03/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares, no par value 03/13/2025 J(1) 48,333 D (1) 0 I By Title 19 Acies(2)
Common Shares, no par value 2,435,029 I By Title 19 Promis(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On March 13, 2025, the ownership of Title 19 Acies, a series of a Delaware limited liability company, was assigned to Skye Peak Partners LLC, a Delaware limited liability company ("SPP"), effective as of January 1, 2025. In connection with such assignment, the management of Title 19 Acies changed from the Reporting Person as sole manager to Emmett Gordon and Michael Youniss as managers, and the Reporting Person does not otherwise have investment control over the shares of the Issuer held by SPP. Accordingly, the Reporting Person no longer has a pecuniary interest in shares of the Issuer held by Title 19 Acies.
2. By Title 19 Acies, of which the Reporting Person was the sole manager.
3. By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
Remarks:
The Issuer's Form 10-Q filed on August 13, 2025 provides that as of such date, the Issuer had 51,806,497 Common Shares outstanding. Based on this number and other shares included in the denominator of the calculation of the Reporting Person's ownership, the Reporting Person's ownership has dropped below 10% as of the date of filing this late Form 4. However, based on the publicly available number of outstanding shares reported prior to when this Form 4 was due, the Reporting Person held more than 10% at such time the Form 4 was due.
/s/ Michael S. Gordon 08/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Michael S. Gordon report on Form 4 for PMN?

The Form 4 reports a disposition of 48,333 common shares on 03/13/2025, and discloses indirect holdings of 2,435,029 shares via Title 19 Promis.

Why did Gordons reported ownership fall below 10%?

The filing states that after using the issuers reported outstanding share count of 51,806,497, Gordons ownership dropped below 10% as of the Form 4 filing date.

What change occurred with Title 19 Acies?

Title 19 Acies was assigned to Skye Peak Partners LLC effective 01/01/2025, and management changed from Gordon as sole manager to Emmett Gordon and Michael Youniss, removing Gordons investment control over those shares.

When was the Form 4 signed?

The Form 4 bears the reporting persons signature dated 08/14/2025.

Does the Form 4 indicate any derivative transactions?

No. Table II for derivative securities contains no reported transactions in this filing.
Promis Neuroscie

NASDAQ:PMN

PMN Rankings

PMN Latest News

PMN Latest SEC Filings

PMN Stock Data

22.88M
20.53M
28.66%
28.8%
5.41%
Biotechnology
Pharmaceutical Preparations
Link
Canada
TORONTO